Skip to main content
Northwestern University Feinberg School of Medicine
Craig Horbinski Lab

Selected Publications

  1. Kim KS, Habashy K, Gould A, Zhao J, Najem H, Amidei C, Saganty R, Arrieta VA, Dmello C, Chen L  et al.  Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood-brain barrier opening: A novel combinatorial immunotherapy regimen for gliomas.  Neuro Oncol  2024 Nov 04;26(11):2044-2060. doi:10.1093/neuonc/noae135
  2. Schubert MC, Soyka SJ, Tamimi A, Maus E, Schroers J, Wißmann N, Reyhan E, Tetzlaff SK, Yang Y, Denninger R  et al.  Deep intravital brain tumor imaging enabled by tailored three-photon microscopy and analysis.  Nat Commun  2024 Sep 10;15(1):7383. pii:7383
  3. An S, McCortney K, Walshon J, Leonard K, Wray B, McCord M, DeCuypere M, Horbinski C  Methylation profiling of plasma cell-free DNA in pediatric brain tumor patients.  Acta Neuropathol  2024 Aug 26;148(1):29. doi:10.1007/s00401-024-02795-x
  4. Wang JZ, Patil V, Landry AP, Gui C, Ajisebutu A, Liu J, Saarela O, Pugh SL, Won M, Patel Z  et al.  Molecular classification to refine surgical and radiotherapeutic decision-making in meningioma.  Nat Med  2024 Aug 21;. doi:10.1038/s41591-024-03167-4
  5. Yang Y, Wadhwani N, Shimomura A, Zheng S, Chandler J, Lesniak MS, Tate MC, Sonabend AM, Kalapurakal J, Horbinski C  et al.  Long-term outcomes of central neurocytoma - an institutional experience.  J Neurooncol  2024 Aug;169(1):195-201. doi:10.1007/s11060-024-04713-3
  6. Smith H, Jean J, Duckett D, Vormittag-Nocito E, Nezami BG, Jennings LJ, Ahrendsen JT, Yang XJ, Primdahl D, Conway K  et al.  Diagnostic utility of multimodal advanced molecular testing to classify metastases of unknown primaries: A case of a patient with no known medical history.  J Neuropathol Exp Neurol  2024 Jul 31;. pii:nlae086
  7. Thirunavu V, Drumm M, McCord M, Steffens A, Youngblood MW, Nandoliya KR, Smith H, Walshon J, McCortney K, Magill ST  et al.  Optimizing the use of Ki-67 proliferative index as a prognostic biomarker in meningiomas using digital analysis.  J Neurosurg  2024 Jul 05;:1-11. doi:10.3171/2024.4.JNS232857
  8. Kostelecky N, Wadhwani N, Golubovich I, Vormittag-Nocito E, Gao J, Jennings L, Caron M, Jamshidi P, Ahrendsen JT, Castellani R  et al.  Transdifferentiation of metastatic melanoma into cerebellar angiosarcoma.  J Neuropathol Exp Neurol  2024 Jul 04;. pii:nlae075
  9. Singer L, Singer J, Horbinski C, Penas-Prado M, Lukas RV  Immunotherapy for Solitary Fibrous Tumor (Hemangiopericytoma): A Unique Treatment Approach for a Rare Central Nervous System Tumor.  Neurologist  2024 Jul 01;29(4):250-253. doi:10.1097/NRL.0000000000000572
  10. Rudà R, Horbinski C, van den Bent M, Preusser M, Soffietti R  IDH inhibition in gliomas: from preclinical models to clinical trials.  Nat Rev Neurol  2024 Jul;20(7):395-407. doi:10.1038/s41582-024-00967-7
  11. Ghorbani A, Chatanaka MK, Avery LM, Wang M, Brown J, Cohen R, Gorham T, Misaghian S, Padmanabhan N, Romero D  et al.  Glial fibrillary acidic protein, neurofilament light, matrix metalloprotease 3 and fatty acid binding protein 4 as non-invasive brain tumor biomarkers.  Clin Proteomics  2024 Jun 15;21(1):41. pii:41
  12. Gruchala T, Smith H, Khan O, Jennings L, Santana-Santos L, Vormittag-Nocito E, Horbinski C  Epithelial differentiation mimicking tumor-to-tumor metastasis in an isocitrate dehydrogenase wild-type glioblastoma.  Neurooncol Adv  2024;6(1):vdae081. pii:vdae081
  13. Khan F, Lin Y, Ali H, Pang L, Dunterman M, Hsu WH, Frenis K, Grant Rowe R, Wainwright DA, McCortney K  et al.  Lactate dehydrogenase A regulates tumor-macrophage symbiosis to promote glioblastoma progression.  Nat Commun  2024 Mar 05;15(1):1987. pii:1987
  14. Romay MC, Knutsen RH, Ma F, Mompeón A, Hernandez GE, Salvador J, Mirkov S, Batra A, Sullivan DP, Procissi D  et al.  Age-related loss of Notch3 underlies brain vascular contractility deficiencies, glymphatic dysfunction, and neurodegeneration in mice.  J Clin Invest  2024 Jan 16;134(2). pii:e166134
  15. Nabors B, Portnow J, Hattangadi-Gluth J, Horbinski C  NCCN CNS tumor guidelines update for 2023.  Neuro Oncol  2023 Dec 08;25(12):2114-2116. doi:10.1093/neuonc/noad169
  16. Lukas RV, Horbinski C  Glioma Response to IDH Inhibition: Real-World Experience.  Clin Cancer Res  2023 Dec 01;29(23):4709-4710. doi:10.1158/1078-0432.CCR-23-2164
  17. Johnson M, Bell A, Lauing KL, Ladomersky E, Zhai L, Penco-Campillo M, Shah Y, Mauer E, Xiu J, Nicolaides T  et al.  Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence.  Clin Cancer Res  2023 Dec 01;29(23):4973-4989. doi:10.1158/1078-0432.CCR-23-0834
  18. McCord M, Jamshidi P, Thirunavu V, Santana-Santos L, Vormittag-Nocito E, Dittman D, Parker S, Baczkowski J, Jennings L, Walshon J  et al.  Variant allelic frequencies of driver mutations can identify gliomas with potentially false-negative MGMT promoter methylation results.  Acta Neuropathol Commun  2023 Nov 02;11(1):175. pii:175
  19. Meredith DM, Cooley LD, Dubuc A, Morrissette J, Sussman RT, Nasrallah MP, Rathbun P, Yap KL, Wadhwani N, Bao L  et al.  ROS1 Alterations as a Potential Driver of Gliomas in Infant, Pediatric, and Adult Patients.  Mod Pathol  2023 Nov;36(11):100294. doi:10.1016/j.modpat.2023.100294
  20. Murnan KM, Horbinski C, Stegh AH  Redox Homeostasis and Beyond: The Role of Wild-Type Isocitrate Dehydrogenases for the Pathogenesis of Glioblastoma.  Antioxid Redox Signal  2023 Nov;39(13-15):923-941. doi:10.1089/ars.2023.0262
  21. Youngblood MW, Erson-Omay Z, Li C, Najem H, Coșkun S, Tyrtova E, Montejo JD, Miyagishima DF, Barak T, Nishimura S  et al.  Super-enhancer hijacking drives ectopic expression of hedgehog pathway ligands in meningiomas.  Nat Commun  2023 Oct 07;14(1):6279. pii:6279
  22. Khan F, Lin Y, Ali H, Pang L, Dunterman M, Hsu WH, Frenis K, Rowe RG, Wainwright D, McCortney K  et al.  LDHA-regulated tumor-macrophage symbiosis promotes glioblastoma progression.  Res Sq  2023 Oct 05;. pii:rs.3.rs-3401154
  23. Pang L, Dunterman M, Guo S, Khan F, Liu Y, Taefi E, Bahrami A, Geula C, Hsu WH, Horbinski C  et al.  Kunitz-type protease inhibitor TFPI2 remodels stemness and immunosuppressive tumor microenvironment in glioblastoma.  Nat Immunol  2023 Oct;24(10):1654-1670. doi:10.1038/s41590-023-01605-y
  24. Stamm B, DiBiase R, Lee J, Primdahl D, Malavia T, Dixit K, Horbinski C, Kostelecky N, Elhodaky M, Potts MB  et al.  A Woman With Multifocal Ischemic Strokes and Progressive Cognitive Impairment due to Intravascular Lymphoma.  Stroke  2023 Oct;54(10):e448-e451. doi:10.1161/STROKEAHA.123.043934
  25. Goenka A, Song X, Tiek D, Iglesia RP, Lu M, Zeng C, Horbinski C, Zhang W, Hu B, Cheng SY  Oncogenic long noncoding RNA LINC02283 enhances PDGF receptor A-mediated signaling and drives glioblastoma tumorigenesis.  Neuro Oncol  2023 Sep 05;25(9):1592-1604. doi:10.1093/neuonc/noad065
  26. Zeng C, Song X, Zhang Z, Cai Q, Cai J, Horbinski C, Hu B, Cheng SY, Zhang W  Dissection of transcriptomic and epigenetic heterogeneity of grade 4 gliomas: implications for prognosis.  Acta Neuropathol Commun  2023 Aug 14;11(1):133. pii:133
  27. Jo J, Diaz M, Horbinski C, Mackman N, Bagley S, Broekman M, Rak J, Perry J, Pabinger I, Key NS  et al.  Epidemiology, biology, and management of venous thromboembolism in gliomas: An interdisciplinary review.  Neuro Oncol  2023 Aug 03;25(8):1381-1394. doi:10.1093/neuonc/noad059
  28. Budhiraja S, Najem H, Tripathi S, Wadhawani NR, Horbinski C, McCord M, Lenzen AC, Heimberger AB, DeCuypere M  Immunobiology and Cytokine Modulation of the Pediatric Brain Tumor Microenvironment: A Scoping Review.  Cancers (Basel)  2023 Jul 18;15(14). pii:3655
  29. Galbraith K, Vasudevaraja V, Serrano J, Shen G, Tran I, Abdallat N, Wen M, Patel S, Movahed-Ezazi M, Faustin A  et al.  Clinical utility of whole-genome DNA methylation profiling as a primary molecular diagnostic assay for central nervous system tumors-A prospective study and guidelines for clinical testing.  Neurooncol Adv  2023;5(1):vdad076. pii:vdad076
  30. Drumm MR, Wang W, Sears TK, Bell-Burdett K, Javier R, Cotton KY, Webb B, Byrne K, Unruh D, Thirunavu V  et al.  Postoperative risk of IDH-mutant glioma-associated seizures and their potential management with IDH-mutant inhibitors.  J Clin Invest  2023 Jun 15;133(12). pii:e168035
  31. Lucas CH, Mirchia K, Seo K, Najem H, Chen W, Zakimi N, Choudhury A, Liu SJ, Phillips J, Magill S  et al.  Spatial genomic, biochemical, and cellular mechanisms drive meningioma heterogeneity and evolution.  Res Sq  2023 May 15;. pii:rs.3.rs-2921804
  32. Zhang Y, Nguyen CC, Zhang NT, Fink NS, John JD, Venkatesh OG, Roe JD, Hoffman SC, Lesniak MS, Wolinsky JP  et al.  Neurological applications of belzutifan in von Hippel-Lindau disease.  Neuro Oncol  2023 May 04;25(5):827-838. doi:10.1093/neuonc/noac234
  33. Ghorbani A, Avery LM, Sohaei D, Soosaipillai A, Richer M, Horbinski C, McCortney K, Xu W, Diamandis EP, Prassas I  Discovery of novel glioma serum biomarkers by proximity extension assay.  Clin Proteomics  2023 Mar 24;20(1):12. pii:12
  34. Raleigh D, Chen W, Choudhury A, Youngblood M, Polley MY, Lucas CH, Mirchia K, Maas S, Suwala A, Won M  et al.  Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses.  Res Sq  2023 Mar 20;. pii:rs.3.rs-2663611
  35. Burdett KB, Unruh D, Drumm M, Steffens A, Lamano J, Judkins J, Schwartz M, Javier R, Amidei C, Lipp ES  et al.  Determining venous thromboembolism risk in patients with adult-type diffuse glioma.  Blood  2023 Mar 16;141(11):1322-1336. doi:10.1182/blood.2022017858
  36. Youngblood MW, Tran AN, Wang W, An S, Scholtens D, Zhang L, O'Shea K, Pokorny JL, Magill ST, Sachdev S  et al.  Docetaxel targets aggressive methylation profiles and serves as a radiosensitizer in high-risk meningiomas.  Neuro Oncol  2023 Mar 14;25(3):508-519. doi:10.1093/neuonc/noac206
  37. Jamshidi P, McCord M, Galbraith K, Santana-Santos L, Jennings LJ, Snuderl M, Horbinski C  Variant allelic frequency of driver mutations predicts success of genomic DNA methylation classification in central nervous system tumors.  Acta Neuropathol  2023 Mar;145(3):365-367. doi:10.1007/s00401-023-02542-8
  38. Sullivan J, Chandler J, Lesniak M, Tate M, Sonabend A, Kalapurakal J, Horbinski C, Lukas R, Kumthekar P, Sachdev S  Clinical outcomes for pleomorphic xanthoastrocytoma patients: an institutional experience.  Res Sq  2023 Feb 03;. pii:rs.3.rs-2535551
  39. Miller JJ, Gonzalez Castro LN, McBrayer S, Weller M, Cloughesy T, Portnow J, Andronesi O, Barnholtz-Sloan JS, Baumert BG, Berger MS  et al.  Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.  Neuro Oncol  2023 Jan 05;25(1):4-25. doi:10.1093/neuonc/noac207
  40. Horbinski C, Nabors LB, Portnow J, Baehring J, Bhatia A, Bloch O, Brem S, Butowski N, Cannon DM, Chao S  et al.  NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022.  J Natl Compr Canc Netw  2023 Jan;21(1):12-20. doi:10.6004/jnccn.2023.0002
  41. Cimino PJ, Ketchum C, Turakulov R, Singh O, Abdullaev Z, Giannini C, Pytel P, Lopez GY, Colman H, Nasrallah MP  et al.  Expanded analysis of high-grade astrocytoma with piloid features identifies an epigenetically and clinically distinct subtype associated with neurofibromatosis type 1.  Acta Neuropathol  2023 Jan;145(1):71-82. doi:10.1007/s00401-022-02513-5
  42. Bollu LR, Bommi PV, Monsen PJ, Zhai L, Lauing KL, Bell A, Kim M, Ladomersky E, Yang X, Platanias LC  et al.  Identification and Characterization of a Novel Indoleamine 2,3-Dioxygenase 1 Protein Degrader for Glioblastoma.  J Med Chem  2022 Dec 08;65(23):15642-15662. doi:10.1021/acs.jmedchem.2c00771
  43. McCord M, Bartom E, Burdett K, Baran A, Eckerdt FD, Balyasnikova IV, McCortney K, Sears T, Cheng SY, Sarkaria JN  et al.  Modeling Therapy-Driven Evolution of Glioblastoma with Patient-Derived Xenografts.  Cancers (Basel)  2022 Nov 09;14(22). pii:5494
  44. Smith HL, Wadhwani N, Horbinski C  Major Features of the 2021 WHO Classification of CNS Tumors.  Neurotherapeutics  2022 Oct;19(6):1691-1704. doi:10.1007/s13311-022-01249-0
  45. Lauko A, Volovetz J, Turaga SM, Bayik D, Silver DJ, Mitchell K, Mulkearns-Hubert EE, Watson DC, Desai K, Midha M  et al.  SerpinB3 drives cancer stem cell survival in glioblastoma.  Cell Rep  2022 Sep 13;40(11):111348. doi:10.1016/j.celrep.2022.111348
  46. Horbinski C, Berger T, Packer RJ, Wen PY  Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours.  Nat Rev Neurol  2022 Sep;18(9):515-529. doi:10.1038/s41582-022-00679-w
  47. Santana-Santos L, Kam KL, Dittmann D, De Vito S, McCord M, Jamshidi P, Fowler H, Wang X, Aalsburg AM, Brat DJ  et al.  Validation of Whole Genome Methylation Profiling Classifier for Central Nervous System Tumors.  J Mol Diagn  2022 Aug;24(8):924-934. doi:10.1016/j.jmoldx.2022.04.009
  48. Dmello C, Sonabend A, Arrieta VA, Zhang DY, Kanojia D, Chen L, Gould A, Zhang J, Kang SJ, Winter J  et al.  Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma.  Clin Cancer Res  2022 Jul 15;28(14):3156-3169. doi:10.1158/1078-0432.CCR-21-2563
  49. Rammohan N, Ho A, Saxena M, Bajaj A, Kruser TJ, Horbinski C, Korutz A, Tate M, Sachdev S  Tumor-associated alterations in white matter connectivity have prognostic significance in MGMT-unmethylated glioblastoma.  J Neurooncol  2022 Jul;158(3):331-339. doi:10.1007/s11060-022-04018-3
  50. Najem H, Ott M, Kassab C, Rao A, Rao G, Marisetty A, Sonabend AM, Horbinski C, Verhaak R, Shankar A  et al.  Central nervous system immune interactome is a function of cancer lineage, tumor microenvironment, and STAT3 expression.  JCI Insight  2022 May 09;7(9). pii:e157612